Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP …

MeSH — NLM indexing Adult Antiviral Agents / adverse effects Antiviral Agents / therapeutic use Child Counseling / methods Hepatitis B Vaccines / administration & dosage Hepatitis B, Chronic / diagnosis Hepatitis B, Chronic / drug therapy Hepatitis B, Chronic / prevention & control Humans Mass Screening / methods

Staff actions

Download PDF

Files are for authorised use within BioPredictive partner channels only.

Fibrotest Actitest Guideline Independent Group United States

Authors (9)

Terrault NA — Division of Gastroenterology/Hepatology, University of California San Francisco, San Francisco, CA.
Lok ASF — Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI.
McMahon BJ — Liver Diseases and Hepatitis Program, Alaska NativeTribal Health Consortium, Anchorage, AK.
Chang KM — Division of Gastroenterology, Corporal Michael J. Crescenz VA Medical Center & University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Hwang JP — Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Terrault NA — Division of Gastroenterology/Hepatology, University of California San Francisco, San Francisco, CA.
Lok ASF — Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI.
McMahon BJ — Liver Diseases and Hepatitis Program, Alaska NativeTribal Health Consortium, Anchorage, AK.
Chang KM — Division of Gastroenterology, Corporal Michael J. Crescenz VA Medical Center & University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Hwang JP — Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jonas MM — Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA.
Brown RS — Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY.
Bzowej NH — Ochsner Medical Center, New Orleans, LA.
Wong JB — Division of Clinical Decision Making, Tufts Medical Center, Tufts University School of Medicine, Boston, MA.

Citation

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800.

Identifiers

DOI: 10.1002/hep.29800
PMID: 29405329
PMC: PMC2846968

Tests

Liver diseases

Liver injuries

Subjects

Region

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

More by Terrault NA

Management of the patient with SVR.

More on the same topic

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Toward non-invasive assessment strategies in autoimmune hepatitis.

Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.